This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at email@example.com or call 800-767-3771 ext. 9339.
For Immediate Release
Chicago, IL – September 12, 2012 – Zacks Equity Research highlights Valmont Industries, Inc. ( VMI - Analyst Report ) as the Bull of the Day andWalter Energy Inc. ( WLT - Analyst Report ) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on CareFusion ( CFN - Snapshot Report ) , Cardinal Health ( CAH - Analyst Report ) and Natus Medical ( BABY - Snapshot Report ) .
Full analysis of all these stocks is available at http://at.zacks.com/?id=2678.
Here is a synopsis of all five stocks:
We are maintaining our Outperform recommendation onValmont Industries, Inc. ( VMI - Analyst Report ) following its strong second-quarter 2012 results. Revenues and earnings topped Zacks Consensus Estimates. Profit jumped 31% year over year on healthy revenue growth, boosted by a solid performance in the company's Utility Support Structures division.
Valmont is witnessing significant strength in the irrigation market and improving demand for its utility transmission structure. The company expects to post double-digit earnings growth in 2012 despite the European slowdown. The outlook for irrigation equipment is strong while demand for Utility Support Structures is expected to rise.
Healthy order activity and a growing backlog support expectations for a strong 2012. Our long-term Outperform recommendation indicates that it would exceed the broader market. Our price target of $153 is based on 18.3x our fiscal 2012 earnings estimate.
We downgrade our recommendation onWalter Energy Inc. ( WLT - Analyst Report ) to Underperform from Neutral as the current depressed trend in thermal coal prices and increasing cost from the company's U.K. and Canadian operations take a toll on the company's profitability. We believe these depressed trends will persist in the coming quarters.
The obligation to fulfill environmental regulation is also expected to limit Walter's cost-cutting program. Also, the company's narrow capex outlook for 2012 is expected to shake investor confidence. The failure to add reserves and fluctuations in input prices are other negatives that could offset Walter's growth.
The trailing 12-month EV/EBITDA multiple is lower than the industry average. Our $28.00 target price is based on 2.7x trailing 12-month cash flow per share.
Latest Posts on the Zacks Analyst Blog:
CareFusion: A Strong Buy
Rising earnings estimates on the back of strong fourth quarter and fiscal 2012 results helpedCareFusion ( CFN - Snapshot Report ) achieve a Zacks #1 Rank (Strong Buy) on September 11. Moreover, this global medical technology company has delivered positive earnings surprises in six of the last seven quarters with an average beat of 5.1%.
With a decent one-year return of 17.2% and a history of beating quarterly earnings estimates, this stock offers an attractive investment opportunity.
The Rank Driver
Several factors such as a strong fourth quarter, strategic initiatives to re-align its portfolio, acquisitions synergistic to product line and geographical reach as well as share buybacks and an attractive valuation are driving the stock. While the company is dogged by product recalls, it is continuously working on investing in quality systems.
CareFusion reported its fourth quarter and fiscal 2012 results on August 9, 2012. The company reported 4% year-over-year revenue growth (at constant exchange rate or CER) to gross $968 million during the quarter, surpassing the Zacks Consensus Estimate of $956 million. Revenues increased 5% in fiscal 2012 to $3.6 billion. The strength of the Medical Systems segment helped CareFusion reach the high end of its revenue guidance range of 3−5%.
Adjusted earnings per share (“EPS") from continuing operations came in at 51 cents for the fourth quarter and $1.78 for fiscal 2012, which is in the middle of the $1.75−$1.80 guidance range provided earlier.
The Medical Systems segment recorded 10% revenue growth at CER to $646 million during the quarter. Record installations of Infusion Systems and double-digit sales growth in both Respiratory Technologies and Dispensing Technologies contributed to the growth of the Medical Systems business. Procedural Solutions, however, recorded a 6% decline at CER to $322 million due to lower sales in the Specialty Disposables business arising from a difficult comparison.
The company is progressing with its sales force realignment. The newly formed surgical and vascular teams are gaining traction in their new territories thereby strengthening the company’s position.
CareFusion continued with its share repurchase program. The company repurchased 1.9 million shares for $50 million during the quarter and 3.9 million shares for $100 million during the fiscal.
For fiscal 2013, CareFusion expects to report 1−3% revenue growth (at CER) resulting in adjusted EPS of $2.11−$2.21. The two segments of the company – Medical Systems and Procedural Solutions – are expected to grow at 1–3% and 0–2%, respectively.
The company is also targeting a 12−14% compounded EPS growth rate through fiscal 2015 on the back of capital allocation in the form of suitable acquisitions and share buyback programs.
Earnings Estimate Revisions
Given CareFusion’s solid performance in the fourth quarter, the Zacks Consensus Estimate for fiscal 2013 increased 9.1% to $2.16 per share based on 10 upward estimate revisions over the last 30 days. The current estimate implies year-over-year growth of 21.2%.
For fiscal 2014, 11 out of 12 estimates were revised higher over the same time frame, raising the Zacks Consensus Estimate by 7.2% to $2.37 per share, implying year-over-year growth of 9.9%.
Valuation of CareFusion looks compelling compared to its peers by most metrics. Based on 2013 earnings estimates, the company is trading at a price-to-earnings (P/E) of 12.85x, a 16.6% discount to the peer group average of 15.41x. The price-to-book of 1.19x is at a 34.6% discount to the peer group average of 1.82x. Valuation looks attractive with respect to the price-to-sales (P/Sales) ratio as well. The P/Sales ratio of the company stood at 1.69, a 13.3% discount to the peer group average of 1.95.
About the Company
CareFusion, with market capitalization of $6.14 billion, is a global medical technology company with a portfolio encompassing IV infusion, medication and supply dispensing, respiratory care, infection prevention and surgical instruments to customers in the US and over 130 countries throughout the world. The company’s customer profile in the US includes hospitals, ambulatory surgical centers, clinics, long-term care facilities and physician offices. CareFusion, incorporated in Delaware, was spun off fromCardinal Health ( CAH - Analyst Report ) on August 31, 2009.
The company has grown both through the organic and the inorganic route. The latest acquisition, in June 2012, was that of U.K. Medical Limited, a leading distributor of medical products to the National Health Service and private health care sector in the United Kingdom. Earlier, in April 2012, in a strategic decision to simplify its operations, CareFusion sold its Nicolet neurodiagnostic and monitoring products business toNatus Medical ( BABY - Snapshot Report ) for $58 million.
Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649.
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment
Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4582.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339
Please login to Zacks.com or register to post a comment.